Jae Hyuk Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jae Hyuk Choi has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Jeehoon Kim
Department of Physics, Pohang University of Science and Technology, Pohang 37673, South Korea
2 shared publications - Jinyoung Yun
Department of Physics, Pohang University of Science and Technology 1 , Pohang 37673, Republic of Korea
2 shared publications - Nestor Haberkorn
Instituto Balseiro, Universidad Nacional de Cuyo and Comisión Nacional de Energía Atómica, Av. Bustillo 9500, 8400 San Carlos de Bariloche, Argentina
2 shared publications - Chan Seok Park
Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
1 shared publication - Dae Young Cheon
Division of Cardiology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
1 shared publication - Dae-Gyun Park
Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University, Seoul, South Korea
1 shared publication
Latest Publications
- Open Access
- 30 April 2025
- Published by Korean Society of Cardiovascular Disease Prevention in Cardiovascular Prevention and Pharmacotherapy
- Vol. 7 (2) , 38-43
Ultra-low-dose direct oral anticoagulants in vulnerable patients with atrial fibrillation or coronary artery disease
Direct oral anticoagulants (DOACs) have largely supplanted warfarin for stroke prevention in atrial fibrillation due to their superior safety and efficacy profiles. Although standard dosing regimens are well-established, lower doses—often referred to as ultra‐low-dose (ULD) DOACs—have been investigated in selected populations to balance thrombotic and bleeding risks. The concept of ULD DOACs was first introduced in the 2013 European Heart Rhythm Association Practical Guide specifically for post‐acute coronary syndrome patients with residual thrombotic risk. Clinical trials, including ATLAS ACS-TIMI 51 and COMPASS, demonstrated that rivaroxaban 2.5 mg twice a day reduced ischemic events when combined with aspirin, although this benefit was accompanied by an increased risk of major bleeding. Similarly, the ELDERCARE-AF trial revealed that edoxaban 15 mg once a day effectively prevented stroke in frail older patients. Conversely, evidence supporting ULDs of dabigatran and apixaban remains limited. Despite their potential benefits, inappropriate dose reductions based on subjective physician judgment rather than rigorous clinical guidelines may result in suboptimal anticoagulation and a heightened risk of thromboembolic events. This review explores the indications, supporting evidence, and potential risks associated with ULD DOACs, underscoring the need for well-designed studies to establish clear guidelines.
- 30 April 2025
- Published by Korean Society of Cardiovascular Disease Prevention in Cardiovascular Prevention and Pharmacotherapy
- Vol. 7 (2) , 38-43
Open AccessUltra-low-dose direct oral anticoagulants in vulnerable patients with atrial fibrillation or coronary artery disease
Direct oral anticoagulants (DOACs) have largely supplanted warfarin for stroke prevention in atrial fibrillation due to their superior safety and efficacy profiles. Although standard dosing regimens are well-established, lower doses—often referred to as ultra‐low-dose (ULD) DOACs—have been investigated in selected populations to balance thrombotic and bleeding risks. The concept of ULD DOACs was first introduced in the 2013 European Heart Rhythm Association Practical Guide specifically for post‐acute coronary syndrome patients with residual thrombotic risk. Clinical trials, including ATLAS ACS-TIMI 51 and COMPASS, demonstrated that rivaroxaban 2.5 mg twice a day reduced ischemic events when combined with aspirin, although this benefit was accompanied by an increased risk of major bleeding. Similarly, the ELDERCARE-AF trial revealed that edoxaban 15 mg once a day effectively prevented stroke in frail older patients. Conversely, evidence supporting ULDs of dabigatran and apixaban remains limited. Despite their potential benefits, inappropriate dose reductions based on subjective physician judgment rather than rigorous clinical guidelines may result in suboptimal anticoagulation and a heightened risk of thromboembolic events. This review explores the indications, supporting evidence, and potential risks associated with ULD DOACs, underscoring the need for well-designed studies to establish clear guidelines.
- Open Access
- 25 March 2024
- Published by AIP Publishing in Applied Physics Letters
- Vol. 124 (13)
The magnetic states of a van der Waals ferromagnet CrGeTe3 probed by vector-field magnetic force microscopy
We present a study on the magnetic domain configuration in the van der Waals ferromagnet CrGeTe3 using a vector-field cryogenic magnetic force microscopy. Our investigation demonstrates the influence of magnetic fields strength and angle on the magnetic domain configuration, showing the coexistence of striped and spike-like magnetic domains. This study contributes to understanding the impact of uniaxial magnetic anisotropy on the domain configuration of van der Waals ferromagnets, offering insights into stabilizing different domain patterns.
- 25 March 2024
- Published by AIP Publishing in Applied Physics Letters
- Vol. 124 (13)
Open AccessThe magnetic states of a van der Waals ferromagnet CrGeTe3 probed by vector-field magnetic force microscopy
We present a study on the magnetic domain configuration in the van der Waals ferromagnet CrGeTe3 using a vector-field cryogenic magnetic force microscopy. Our investigation demonstrates the influence of magnetic fields strength and angle on the magnetic domain configuration, showing the coexistence of striped and spike-like magnetic domains. This study contributes to understanding the impact of uniaxial magnetic anisotropy on the domain configuration of van der Waals ferromagnets, offering insights into stabilizing different domain patterns.
- Open Access
- 29 January 2024
- Published by AIP Publishing in Applied Physics Letters
- Vol. 124 (5)
Interplay between metastable magnetic domains and superconducting vortices in a ferromagnet–superconductor hybrid
The interplay between superconductivity and magnetism has been a subject of significant interest for decades. While extensive research has focused on modifying the superconducting state through a magnetic domain as an independent variable, the manipulation of magnetic domains by the superconducting state has been relatively unexplored, primarily due to their higher stiffness compared to the energy associated with superconducting vortices. In this Letter, we demonstrate the manipulation of magnetic domains by thermally activated superconducting vortices in a ferromagnet/superconductor hybrid. We observe a reversible domain transition between metastable magnetic stripes and bubbles in a Nb/CeRu2Ga2B hybrid induced by vortex motion and the trapped field within the Nb superconducting film. The comparable Curie and superconducting critical temperatures and the presence of magnetic metastable states enable the magnetic domain changes driven by superconducting vortices in this hybrid system.
- 29 January 2024
- Published by AIP Publishing in Applied Physics Letters
- Vol. 124 (5)
Open AccessInterplay between metastable magnetic domains and superconducting vortices in a ferromagnet–superconductor hybrid
The interplay between superconductivity and magnetism has been a subject of significant interest for decades. While extensive research has focused on modifying the superconducting state through a magnetic domain as an independent variable, the manipulation of magnetic domains by the superconducting state has been relatively unexplored, primarily due to their higher stiffness compared to the energy associated with superconducting vortices. In this Letter, we demonstrate the manipulation of magnetic domains by thermally activated superconducting vortices in a ferromagnet/superconductor hybrid. We observe a reversible domain transition between metastable magnetic stripes and bubbles in a Nb/CeRu2Ga2B hybrid induced by vortex motion and the trapped field within the Nb superconducting film. The comparable Curie and superconducting critical temperatures and the presence of magnetic metastable states enable the magnetic domain changes driven by superconducting vortices in this hybrid system.
- Open Access
- 14 September 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-11
PRE-OPerative ECHOcardiograhy for prevention of cardiovascular events after non-cardiac surgery in intermediate- and high-risk patients: protocol for a low-interventional, mixed-cohort prospective study design (PREOP-ECHO)
Background: Cardiac evaluation using transthoracic echocardiography before noncardiac surgery is common in real-world practice. However, evidence supporting preoperative echocardiography is lacking. This study aims to evaluate the additional benefit of preoperative echocardiography in predicting postoperative cardiovascular events (CVE) in noncardiac surgery. Methods: This study is designed as a multicenter, prospective study to assess the utility of preoperative echocardiography in patients undergoing intermediate- or high-risk noncardiac surgery. This trial comprises two studies: (1) a randomized controlled trial (RCT) for patients undergoing intermediate-risk surgery with fewer than three clinical risk factors from the revised cardiac risk index (intermediate-risk group) and (2) a prospective cohort study for patients undergoing intermediate-risk surgery with three or more clinical risk factors, or who undergo high-risk surgery regardless of the number of clinical risk factors (high-risk group). We hypothesize that the use of preoperative echocardiography will reduce postoperative CVEs in patients undergoing intermediate- to high-risk surgery through discovery of and further intervention for unexpected cardiac abnormalities before elective surgery. A total of 2330 and 2184 patients will be enrolled in the two studies. The primary endpoint is a composite of all-cause death; aborted sudden cardiac arrest; type I acute myocardial infarction; clinically diagnosed unstable angina; stress-induced cardiomyopathy; lethal arrhythmia, such as sustained ventricular tachycardia or ventricular fibrillation; and/or newly diagnosed or acutely decompensated heart failure within 30 days after surgery. Discussion: This study will be the first large-scale prospective study examining the benefit of preoperative echocardiography in predicting postoperative CVE. The PREOP-ECHO trial will help doctors identify patients at risk of postoperative CVE using echocardiography and thereby reduce postoperative CVEs. Trial registration: The Clinical Research Information Service KCT0006279 for RCT and KCT0006280 for prospective cohort study. Registered on June 21, 2021.
- 14 September 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-11
Open AccessPRE-OPerative ECHOcardiograhy for prevention of cardiovascular events after non-cardiac surgery in intermediate- and high-risk patients: protocol for a low-interventional, mixed-cohort prospective study design (PREOP-ECHO)
Background: Cardiac evaluation using transthoracic echocardiography before noncardiac surgery is common in real-world practice. However, evidence supporting preoperative echocardiography is lacking. This study aims to evaluate the additional benefit of preoperative echocardiography in predicting postoperative cardiovascular events (CVE) in noncardiac surgery. Methods: This study is designed as a multicenter, prospective study to assess the utility of preoperative echocardiography in patients undergoing intermediate- or high-risk noncardiac surgery. This trial comprises two studies: (1) a randomized controlled trial (RCT) for patients undergoing intermediate-risk surgery with fewer than three clinical risk factors from the revised cardiac risk index (intermediate-risk group) and (2) a prospective cohort study for patients undergoing intermediate-risk surgery with three or more clinical risk factors, or who undergo high-risk surgery regardless of the number of clinical risk factors (high-risk group). We hypothesize that the use of preoperative echocardiography will reduce postoperative CVEs in patients undergoing intermediate- to high-risk surgery through discovery of and further intervention for unexpected cardiac abnormalities before elective surgery. A total of 2330 and 2184 patients will be enrolled in the two studies. The primary endpoint is a composite of all-cause death; aborted sudden cardiac arrest; type I acute myocardial infarction; clinically diagnosed unstable angina; stress-induced cardiomyopathy; lethal arrhythmia, such as sustained ventricular tachycardia or ventricular fibrillation; and/or newly diagnosed or acutely decompensated heart failure within 30 days after surgery. Discussion: This study will be the first large-scale prospective study examining the benefit of preoperative echocardiography in predicting postoperative CVE. The PREOP-ECHO trial will help doctors identify patients at risk of postoperative CVE using echocardiography and thereby reduce postoperative CVEs. Trial registration: The Clinical Research Information Service KCT0006279 for RCT and KCT0006280 for prospective cohort study. Registered on June 21, 2021.